Vimarsana
Biggest News Aggregation in the World

Anbex Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anbex Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anbex Inc Today - Breaking & Trending Today

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 - Vimarsana News

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030

/PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation...

DelveInsight Business Research, LLP: Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 - Vimarsana News

DelveInsight Business Research, LLP: Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of

Mountain Valley pipeline developer registers an in-house lobbyist - Vimarsana News

Mountain Valley pipeline developer registers an in-house lobbyist

Equitrans Midstream has boosted its lobbying footprint in Washington on the heels of this year’s budget ceiling deal.

Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study - Vimarsana News

Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study

/PRNewswire/ -- The global anti-radiation drugs market was valued at US$ 3.4 Bn in 2021 and is anticipated to grow at a CAGR of 9.9% from 2022 to 2031....

Transparency Market Research: Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study - Vimarsana News

Transparency Market Research: Anti-radiation Drugs Market to Reach US$ 9.6 Bn by 2031, TMR Study

Rise in investment in R&D by pharma and biotech companies for the development of effective drugs for acute radiation syndrome or ARS propels market growthIncrease in efforts by pharmaceutical